menu search

axial spondyloarthritis management market is expected to reach us$ 7.3 billion, & expected to grow with a 5.1% cagr during 2023 to 2033 | future market insights, inc.

Hospitals Expected to Hold 40% Of Market Share for axial spondyloarthritis Management Market. North Ame...

March 31, 2023, 11:30 am

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am


Search within

Pages Search Results: